UPDATE : Friday, October 18, 2019
상단여백
Korea carries out new plan to end 'healthcare dine and dash' by foreigners
In May 2015, a Mongolian came to Korea and gained access to health insuranc...
by Lee Han-soo  |  2019-08-09 17:27
라인
South Koreans learn to thank life by experiencing death
Some South Koreans are using an unorthodox method to appreciate life and co...
by Lee Han-soo  |  2019-08-06 06:00
라인
Journal of Stroke tops citation index among domestic journals
Journal of Stroke, a journal by the Korean Stroke Society, ranked No. 1 in ...
by Song Soo-youn  |  2019-07-31 11:38
라인
[Special] Konyang University Hospital aims to soar on crest of Watson
The Watson fever has been waning among domestic medical institutions. Some ...
by Song Soo-youn  |  2019-07-17 11:39
라인
[Special] Physician pushes to create global network for ‘dialysis trips'
For end-stage renal disease (ESRD) patients, traveling overseas is a challe...
by Song Soo-youn  |  2019-07-05 14:53
라인
[Special] End-stage renal disease patients regain joy of travel in Korea
More than 20 Taiwanese tourists visited Beomil Yonsei Internal Medicine Cli...
by Song Soo-youn  |  2019-07-04 15:37
라인
[Special]Korean drugmakers harbor undue expectations on global blockbusters
“The pharmaceutical and biotech industry will lead our economy soon. Even n...
by Jeong Sae-im  |  2019-07-01 16:19
라인
Nation split over WHO's decision on game addiction
The World Health Organization's decision to put excessive gaming on the...
by Lee Han-soo  |  2019-06-27 12:46
라인
[Startups to Watch] 'Noul aims to become major player in eradicating malaria'
Malaria, a mosquito-borne disease, is one of the most common infectious dis...
by Lee Han-soo  |  2019-06-12 11:01
라인
[Photo News]Scenes at ASCO 2019
CHICAGO, Ill. -- The American Society of Clinical Oncology (ASCO) 2019 has ...
by Lee Han-soo, KBR correspondent  |  2019-06-03 11:58
라인
[Pre-ASCO 2019] Yooyoung Pharmaceutical: YYB101 -- refractory solid tumor treatment
Yooyoung Pharmaceutical will present the results of its phase 1 clinical tr...
by Lee Han-soo  |  2019-05-27 14:22
라인
[Pre-ASCO 2019] ABL Bio: ABL001- bispecific antibody with indications for anti-cancer therapy
ABL Bio is set to become the first Korean company to present its poster ses...
by Lee Han-soo  |  2019-05-21 12:47
라인
[Pre-ASCO 2019] Samsung Bioepis: Ontruzant - HER2-positive breast cancer treatment
Samsung Bioepis will continue to present its biosimilar pipeline at ASCO th...
by Lee Han-soo  |  2019-05-17 16:19
라인
[Pre-ASCO 2019] Yuhan: Lazertinib -- non-small cell lung cancer treatment
The core of Yuhan’s announcement at ASCO this year is on the latest results...
by Lee Han-soo  |  2019-05-17 09:57
라인
Medical IT changes China's healthcare landscape
The advancement of information and technology (IT) is quickly changing the ...
by Song Soo-youn  |  2019-05-16 16:33
라인
[Interview with Global Pharmas] ‘Korea’s drug pricing an obstacle for providing optimal treatments to patients’
Like most multinational pharmaceuticals here, Novo Nordisk Korea has concer...
by Lee Han-soo  |  2019-05-10 14:26
라인
[Special] Patients issued 'ultimatum' to Gore. Why?
The artificial vessel supply stoppage crisis seemed almost over with the so...
by Kwak Sung-sun  |  2019-05-10 13:53
라인
[Special]‘K-Medi’s overseas advance will contribute to health of global citizens’
The Division of Global Health Care Affairs at the Ministry of Health and We...
by Kwak Sung-sun  |  2019-04-19 14:22
라인
[Special]‘We hope entire world will experience K-Care’
The Division of Global Health Care at the Ministry of Health and Welfare wa...
by Kwak Sung-sun  |  2019-04-09 11:32
라인
[Special] Interleukin inhibitors Cosentyx, Taltz target psoriasis market
Interleukin inhibitors are rising as the newest psoriasis treatment.Tumor n...
by Kim Yun-mi  |  2019-03-26 14:56
-123456789-
Ministry OKs ATGC's p1, 2 trial for BTXMinistry OKs ATGC's p1, 2 trial for BTX
여백
Most viewed
여백
Opinion
[Column] Digital healthcare for efficient distribution of medical resources
[Column] Digital healthcare for efficient distribution of medical resources
[Reporter’s Notebook] SillaJen should be ashamed of itself
[Reporter’s Notebook] SillaJen should be ashamed of itself
[Column] Drug regulator needs adequate expertise to promote medical devices
[Column] Drug regulator needs adequate expertise to promote medical devices
여백
Back to Top